Strategic Partners A/S

Strategic Partners A/S Book Value per Share

The Book Value per Share of Strategic Partners A/S (STRAP.CO) as of Oct 16, 2026 is 459.75 DKK. In the previous year, Book Value per Share was 481.20 DKK — a change of -4.46% (lower).

Book Value per Share

459.75DKK

YoY

-4.46%

Last updated:

Book Value per Share of Strategic Partners A/S is 2025 459.75 DKK. Book Value per Share of Strategic Partners A/S was 2024 481.20 DKK. It decreases by -4.46% lower compared to the previous year.

The Strategic Partners A/S Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
9,706.23 DKK
Jan 1, 2019
1,324.23 DKK
Jan 1, 2020
15,513.13 DKK
Jan 1, 2021
233.48 DKK
Jan 1, 2022
1,024.35 DKK
Jan 1, 2023
356.05 DKK
Jan 1, 2024
481.20 DKK
Jan 1, 2025
459.75 DKK
The Strategic Partners A/S Book Value per Share history
YEARBook Value per ShareYoY
459.75DKK-4.46%
481.20DKK+35.15%
356.05DKK-65.24%
1,024.35DKK+338.74%
233.48DKK-98.49%
15,513.13DKK+1,071.49%
1,324.23DKK-86.36%
9,706.23DKK-36.94%
15,392.55DKK+3,416.49%
437.73DKK-76.38%
1,853.58DKK-17.05%
2,234.50DKK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Strategic Partners A/S Stock analysis

What does Strategic Partners A/S do? Strategic Partners A/S, listed on the Copenhagen Stock Exchange with ticker STRAP.CO and ISIN DK0062502894, is a Danish biotechnology company operating in the healthcare sector. Based in Copenhagen, the company employs 141 people and went public through an IPO on November 17, 2017. Strategic Partners A/S focuses on the development of treatments for rare diseases, particularly targeting lysosomal storage diseases (LSDs) and protein aggregation disorders. LSDs encompass approximately 50 genetic disorders caused by deficiencies in lysosomal enzymes or other lysosomal components. The company's primary therapeutic candidate, arimoclomol, works by stimulating the production of heat shock proteins, which assist in correcting misfolded proteins or facilitating their removal via lysosomal recycling. Strategic Partners A/S collaborates with academic institutions across Europe and the United States to advance its research and development efforts. The company's website is hosted at https://www.orphazyme.com/, though the provided source description includes unverified details about Orphazyme A/S, which should not be conflated with Strategic Partners A/S. Strategic Partners A/S is dedicated to addressing life-threatening and debilitating rare diseases through innovative biotechnological approaches. The company's operations are centered on preclinical development, with a focus on advancing therapies that target the underlying mechanisms of genetic disorders. Strategic Partners A/S maintains a strong presence in the biotechnology sector, leveraging partnerships and scientific expertise to develop treatments for conditions with limited therapeutic options. The company's activities are aligned with the broader healthcare industry's focus on rare disease research and treatment innovation. Strategic Partners A/S continues to work toward bringing novel therapies to patients suffering from rare and complex genetic disorders. Strategic Partners A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Strategic Partners A/S stock

Book Value per Share of Strategic Partners A/S is 459.75 DKK in 2025.

Book Value per Share of Strategic Partners A/S changed from 481.20 DKK to 459.75 DKK, representing a -4.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Strategic Partners A/S since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Strategic Partners A/S

All Key Metrics — Strategic Partners A/S